Every Form 4 that NewAmsterdam Pharma Company N.V (NAMS) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow NAMS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NAMS filings page.
NewAmsterdam Pharma Co N.V. (NAMS) reported that Vice President, Controller Robert William Gunning received equity compensation awards on September 1, 2026. He was granted options for 14,000 ordinary shares at an exercise price of $24.92 per share, expiring August 31, 2036, plus 3,200 restricted stock units, each representing one ordinary share. The RSUs vest in three equal annual installments beginning September 10, 2026, and 25% of the option shares vest on August 10, 2026, with the remainder vesting in equal monthly installments over the following three years, in each case subject to his continued service. No Rule 10b5-1 trading plan is reported.
NewAmsterdam Pharma Co N.V. (NAMS) reports that Chief Scientific Officer Johannes Jacob Pieter Kastelein, through Futurum B.V. and NAP PoolCo B.V., exercised options for 125,000 Ordinary Shares and on the same day sold 125,000 Ordinary Shares at a weighted average price of $26.91 per share. The options had an exercise price of EUR 1.16392 per share and were held indirectly through Futurum/PoolCo. After these transactions, Kastelein continues to hold 395,229 options indirectly and 53,500 Ordinary Shares directly, including 48,166 shares subject to RSU vesting. All reported trades were executed under a Rule 10b5-1 trading plan adopted by Futurum B.V. on March 31, 2026.
NewAmsterdam Pharma Co N.V. reports that Chief Accounting Officer Louise Frederika Kooij exercised stock options for 105000 ordinary shares on July 20, 2026, then sold 105000 shares in multiple transactions at weighted average prices of $29.9600, $31.0500 and $31.7100 per share, all under a Rule 10b5-1 trading plan adopted on February 23, 2026. Reported holdings include 22000 ordinary shares subject to restricted stock unit awards that remain subject to vesting.
NewAmsterdam Pharma Co N.V.’s Chief Accounting Officer Louise Frederika Kooij reported a combination of option exercises and share sales involving the company’s ordinary shares. On June 22, 2026, she exercised options to acquire a total of 40,000 ordinary shares through two transactions of 15,000 and 25,000 shares at exercise prices of $11.90 and $10.90 per share, respectively.
On the same date, she executed open-market sales totaling 40,000 ordinary shares in two transactions: 39,700 shares at $30.20 per share and 300 shares at a weighted average price of $30.73, with individual trade prices ranging from $29.73 to $30.72 per share. Following these transactions, her direct holdings continue to include 22,000 ordinary shares subject to restricted stock unit awards that remain subject to vesting.
NewAmsterdam Pharma’s Chief Accounting Officer Louise Frederika Kooij reported an exercise-and-sell transaction in Ordinary Shares. On May 26, 2026, she exercised options to acquire a total of 65,000 shares at exercise prices of $10.00 and $10.90 per share.
That same day she completed an open-market sale of 65,000 Ordinary Shares at a weighted average price of $35.69, with individual trades ranging from $35.12 to $36.09 per share. After these transactions she directly holds 24,353 Ordinary Shares, including 22,000 shares subject to restricted stock unit awards that continue to vest over time.
NewAmsterdam Pharma Co N.V. director Louis G. Lange reported open-market sales of a total of 44,619 Ordinary Shares on March 11, 2026. He sold 44,173 shares at a weighted average price of $30.41 per share and 446 shares at a weighted average price of $31.23 per share. After these sales, he directly owns 10,360 Ordinary Shares. The prices reflect multiple trades in ranges from $30.11 to $31.31 per share.
NewAmsterdam Pharma director Louis G. Lange reported a mix of warrant exercises and share sales. On March 9, 2026, he exercised warrants to acquire 44,619 Ordinary Shares at $11.50 per share, leaving him with 54,979 Ordinary Shares held directly.
Separately, on March 6, 2026, a trust associated with him, the LGLange III Trust DTD10, sold 28,186 Ordinary Shares in open-market transactions at a weighted average price of $29.41 per share, within a range of $29.03 to $29.68, and reported no remaining indirect holdings.
NewAmsterdam Pharma Co N.V. Chief Scientific Officer Johannes Jacob Pieter Kastelein, through Futurum B.V., exercised options for 300,000 Ordinary Shares at an exercise price of EUR 1.16392 and sold 300,000 shares in open-market transactions around $30 per share between March 5–9, 2026. The shares and options are held indirectly via Futurum and NAP PoolCo B.V. for his benefit, with the reporting person retaining sole voting and investment control.
NewAmsterdam Pharma Co N.V. CEO Michael H. Davidson reported an option exercise-and-sell transaction on March 2, 2026. He exercised options for 443,707 ordinary shares at EUR 1.16392 per share and sold 443,707 shares at $33.25 per share.
Following the transactions, Davidson held 174,144 ordinary shares directly, with 239,267 options remaining under the reported grant.
NewAmsterdam Pharma Co N.V. CEO Michael H. Davidson reported a multi-day option exercise-and-sell transaction from February 24 through February 26, 2026, under a Rule 10b5-1 trading plan. He exercised options for 306,293 ordinary shares at EUR 1.16392 per share and sold 306,293 shares at prices ranging from $33.63 to $36.68 per share.
The filing also reports a February 26 transfer of 285,715 ordinary shares to a grantor retained annuity trust (GRAT). Following the transactions, Davidson held 174,144 ordinary shares directly and 285,715 shares indirectly through the GRAT, with 682,974 options remaining under the reported grant.
NewAmsterdam Pharma Co N.V. Chief Scientific Officer Johannes Jacob Pieter Kastelein reported open-market sales of company ordinary shares. On February 20, 2026, he sold 14,692 shares at a weighted average price of $35.00 per share and 30,789 shares at a weighted average price of $35.46 per share. The filing notes that these sales occurred through multiple trades, with prices ranging from $34.24 to $35.23 for the first block and from $35.24 to $35.86 for the second block. Following these transactions, he directly owned 53,500 ordinary shares of NewAmsterdam Pharma.
NewAmsterdam Pharma Co N.V.’s Chief Accounting Officer Louise Frederika Kooij reported option exercises and share sales in late January 2026. On January 27, 2026, she exercised 39,816 options at an exercise price of $10.90 per ordinary share and acquired the same number of ordinary shares.
That same day she sold 39,816 ordinary shares at a weighted average price of $32.62 per share, leaving 24,353 ordinary shares directly owned afterward. On January 28, 2026, she exercised another 32,612 options at $10.90 per share and acquired 32,612 ordinary shares, then sold 32,612 ordinary shares at a weighted average price of $31.80 per share.
After these transactions, she directly held 24,353 ordinary shares and 73,134 options (options with a $10.90 exercise price and an expiration date of January 1, 2033). The filing notes that the sale prices are weighted averages across multiple trades within the stated price ranges.
NewAmsterdam Pharma Co N.V.’s Chief Accounting Officer, Louise Frederika Kooij, reported multiple option exercises and share sales in January 2026. On January 23, 2026, she exercised options for 38,172 ordinary shares at an exercise price of $10.90 per share, then sold 25,405 shares at a weighted average price of $33.44 and 12,767 shares at a weighted average price of $34.37, all as ordinary shares.
On January 26, 2026, she exercised additional options for 34,400 ordinary shares at $10.90 per share and sold 34,091 shares at a weighted average price of $32.77 and 309 shares at a weighted average price of $33.45. After these transactions, she directly owned 24,353 ordinary shares and held 145,562 options (right to buy) for ordinary shares.
NewAmsterdam Pharma Co N.V.’s Chief Financial Officer, Mayur Ian Somaiya, reported stock option exercises and related share sales. On January 20 and 21, 2026, he exercised options to acquire 60,216 and 39,784 ordinary shares at an exercise price of $9.26 per share. On the same dates, he sold several blocks of ordinary shares, including 39,712, 19,604, and 24,362 shares at prices referenced in ranges from about $30.17 to $34.31 per share, as detailed in the footnotes.
After these transactions, Somaiya directly held 58,382 ordinary shares and 662,814 option-based derivative securities. The filing states that at least one sale transaction was carried out under a Rule 10b5-1 trading plan, and notes that the underlying option was granted on November 1, 2023 with vesting over four years, subject to continued service.
NewAmsterdam Pharma Co N.V. director Hilde Johanna van der Kamp reported new equity awards. On January 7, 2026, she received 3,400 restricted stock units (RSUs), each representing one ordinary share, granted for no consideration and scheduled to vest in full on the one-year anniversary of the vesting start date, subject to continued service. She also received an option to buy 15,300 ordinary shares at an exercise price of $35.45 per share, with all option shares vesting on January 2, 2027, also conditioned on continued service.
NewAmsterdam Pharma Co. N.V. director Adele M. Gulfo reported equity awards in the form of ordinary shares and options. On January 7, 2026, she received 3,400 restricted stock units (RSUs), each representing one ordinary share, bringing her directly held ordinary shares to 14,260. The RSUs were granted for no cash consideration and will fully vest on the one-year anniversary of the vesting start date, subject to her continued service.
On the same date, she was also granted an option to purchase 15,300 ordinary shares at an exercise price of $35.45 per share, with 15,300 options owned following the grant. All shares underlying the option are scheduled to vest on January 2, 2027, also conditioned on her continued service.
NewAmsterdam Pharma Co N.V.'s Chief Executive Officer and director Michael H. Davidson reported several equity transactions dated January 7, 2026. He sold 11,582 ordinary shares in a pre-arranged sell-to-cover transaction used solely to satisfy tax withholding on vesting restricted stock units, at a weighted average price between $35.24 and $35.59 per share. After this sale, he directly owned 459,859 ordinary shares.
On the same date, he acquired 81,000 restricted stock units (RSUs), each representing one ordinary share. These RSUs were granted for no consideration and are scheduled to vest in three equal annual installments on the first, second and third anniversaries of the vesting start date, contingent on his continued service. He was also granted an option to buy 364,000 ordinary shares at an exercise price of $35.45 per share, expiring on January 7, 2036, with 25% vesting on January 2, 2027 and the remainder vesting monthly over the following three years, subject to continued service.
NewAmsterdam Pharma Co. N.V. director William Lewis reported equity awards from the company. On January 7, 2026, he received 3,400 restricted stock units (RSUs), each representing a contingent right to one ordinary share, granted for no cash consideration. All of these RSUs will vest on the one-year anniversary of the vesting start date, subject to his continued service.
On the same date, he was also granted an option to buy 15,300 ordinary shares, with all underlying shares scheduled to vest on January 2, 2027, also conditioned on continued service. Following the RSU grant, Lewis beneficially owned 10,360 ordinary shares directly.
NewAmsterdam Pharma Co. N.V. director John W. Smither reported equity compensation awards. On January 7, 2026, he received 3,400 restricted stock units (RSUs), each representing one ordinary share, granted for no consideration. All RSUs will vest on the one-year anniversary of the vesting start date, subject to his continued service.
On the same date, he was also granted an option to buy 15,300 ordinary shares at an exercise price of $35.45 per share. These option shares will vest on January 2, 2027, the one-year anniversary of the vesting start date, if he continues in service. After these transactions, he directly owns 10,360 ordinary shares and 15,300 options.
NewAmsterdam Pharma Co. N.V. reported that director Mark C. McKenna received new equity awards. On January 7, 2026, he was granted 3,400 restricted stock units (RSUs), each representing the right to receive one ordinary share. These RSUs will vest in full on the one-year anniversary of the vesting start date, conditioned on his continued service. They were granted for no cash consideration, and following this award he beneficially owns 10,360 ordinary shares directly.
On the same date, McKenna also received an option to acquire 15,300 ordinary shares at an exercise price of $35.45 per share, expiring on January 7, 2036. All shares underlying this option will vest on January 2, 2027, also subject to his continued service, leaving him with 15,300 derivative securities beneficially owned.
NewAmsterdam Pharma Co N.V. director Louis G. Lange reported equity awards granted on January 7, 2026. He received 3,400 restricted stock units, each representing a contingent right to one ordinary share, granted for no consideration and scheduled to vest on the one-year anniversary of the vesting start date, subject to his continued service.
On the same date, he was granted an option to purchase 15,300 ordinary shares at an exercise price of $35.45 per share. All shares underlying this option are scheduled to vest on January 2, 2027, also contingent on continued service. Following these awards, he beneficially owned 10,360 ordinary shares and 15,300 options directly.
NewAmsterdam Pharma Co N.V. Chief Scientific Officer and director Johannes Jacob Pieter Kastelein reported several equity transactions. On January 5, 2026, he sold 6,000 ordinary shares at a weighted average price of $33.25 per share, in a pre-arranged sale made solely to cover tax withholding tied to vesting restricted stock units, described as non-discretionary.
On January 7, 2026, he acquired 25,500 restricted stock units (RSUs) for no consideration, each RSU representing one ordinary share and vesting in three equal annual installments, leaving him with 98,981 ordinary shares beneficially owned. He also received an option to buy 115,000 ordinary shares at an exercise price of $35.45 per share, expiring January 7, 2036, with 25% vesting on January 2, 2027 and the remainder vesting in equal monthly installments over three years, all subject to continued service.
NewAmsterdam Pharma’s Chief Accounting Officer, Louise Frederika Kooij, reported routine equity compensation activity and a related tax-cover sale. On January 5, 2026, she sold 2,647 ordinary shares at a weighted average price of $33.25 per share in a pre-arranged transaction solely to cover tax withholding from restricted stock unit (RSU) vesting. On January 7, 2026, she acquired 12,000 RSUs, each representing one ordinary share, granted for no consideration, with one-third vesting on each of the first three anniversaries of the vesting start date. She also received an option to buy 53,500 ordinary shares at an exercise price of $35.45 per share, expiring on January 7, 2036, with 25% vesting on January 2, 2027 and the remainder vesting in equal monthly installments over the following three years, all subject to continued service.
NewAmsterdam Pharma Co. N.V.’s Chief Financial Officer, Mayur Ian Somaiya, reported several equity transactions in early January 2026. On January 5, 2026, he sold 5,118 ordinary shares at a weighted average price of $33.25 per share to satisfy tax withholding obligations tied to vesting restricted stock units. The filing notes this was a pre-arranged, non-discretionary sell-to-cover transaction.
On January 7, 2026, he acquired 25,500 restricted stock units (RSUs) for no consideration, each representing one ordinary share, with one-third vesting on each of the first three anniversaries of the vesting start date, subject to continued service. He also received an option to buy 115,000 ordinary shares at an exercise price of $35.45 per share, vesting 25% on January 2, 2027 and the remainder in equal monthly installments over the following three years, also contingent on continued service. Following these transactions, he directly beneficially owned 58,382 ordinary shares and 115,000 options.
James N. Topper, a director of NewAmsterdam Pharma Co N.V. (ticker: NAMSW), reported a purchase on Form 4. The filing shows a transaction on 09/15/2025 acquiring 660 ordinary shares at a weighted average price of $23.6953. The filing lists two holdings following the reported transaction: 3,028,524 shares held indirectly by Frazier Life Sciences X, L.P. and 3,801,000 shares held indirectly by Frazier Lifesciences Sponsor LLC. Footnotes state the reported price is a weighted average from multiple purchases priced between $23.46 and $23.75. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Topper on 09/17/2025.